Abstract
Expression of large numbers of different costimulatory integrin ligands (CILs) attributes dendritic cells with an ability to induce primary anti-tumor immune responses. Here, we show that optimized gene transfer of the xenogeneic (human) CILs VCAM-1, MAdCAM-1 and ICAM-1 causes rapid and complete rejection of established mouse EL-4 tumors, and generates prolonged systemic anti-tumor immunity; whereas human E-cadherin weakly slows tumor growth. In each case the immune response was mediated by CD8+ T cells and NK cells, accompanied by augmented tumor-specific cytolytic T cell (CTL) activity involving both the perforin and Fas-ligand pathways. Adoptive transfer of splenocytes from cured mice rapidly cleared established tumors in recipients. The mechanism for CIL-mediated immunity is unknown, but may involve CTL-facilitated tumor lysis, since CTLs were generally twice as efficient at killing CIL-transfected tumor cells than parental tumor cells. Optimized CIL-based gene therapy may provide an approach to complement or replace conventional DC adoptive cell therapy for suppressing tumor growth.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Banchereau J, Steinman RM . Dendritic cells and the control of immunity Nature 1998 39: 245–252
Gao JX et al. Generation of dendritic cell-like antigen-presenting cells in long-term mixed leucocyte culture: phenotype and functional studies Immunol 1997 91: 135–144
Koopman G et al. Adhesion of human B cells to follicular dendritic cells involves both the lymphocyte function-associated antigen 1/intercellular adhesion molecule 1 and very late antigen 4/vascular cell adhesion molecule 1 pathways J Exp Med 1992 173: 1297–1304
Cumberbatch M, Dearman RJ, Kimber I . Adhesion molecule expression by epidermal Langerhans cells and lymph node dendritic cells: a comparison Arch Derm Res 1996 288: 739–744
Starling GC et al. Intercellular adhesion molecule-3 is the predominant co-stimulatory ligand for leukocyte function antigen-1 on human blood dendritic cells Eur J Immunol 1995 25: 2528–2532
Szabo MC, Butcher EC, McEvoy LM . Specialization of mucosal follicular dendritic cells revealed by mucosal addressin-cell adhesion molecule-1 display J Immunol 1997 158: 5584–5588
Debenedette MA, Shahinian A, Mak TW, Watts TH . Costimulation of CD28- lymphocytes by 4–1BB ligand J Immunol 1997 158: 551–559
Anderson DM et al. A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function Nature 1997 390: 175–179
Borriello F, Lederer J, Scott S, Sharpe AH . MRC OX-2 defines a novel T cell costimulatory pathway J Immunol 1997 158: 4548–4554
Ebner S et al. Expression of maturation-/migration-related molecules on human dendritic cells from blood and skin Immunobiol 1998 198: 568–587
Nestle FO et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells Nature Med 1998 4: 328–332
Townsend SE, Allison JP . Tumor rejection after direct costimulation of CD8+ T cells by B7 transfected melanoma cells Science 1993 259: 368–370
Chen L et al. Costimulation of anti-tumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4 Cell 1992 71: 1093–1102
Baskar S et al. Constitutive expression of B7 restores immunogenicity of tumor cells expressing truncated MHC class II molecules Proc Natl Acad Sci USA 1993 90: 5687–5690
Hodge JW, Abrams S, Schlom J, Kantor JA . Induction of antitumor immunity by recombinant vaccinia viruses expressing B7.1 or B7.2 costimulatory molecules Cancer Res 1994 54: 5552–5555
Wei K et al. Xenogeneic ICAM-1 gene transfer suppresses tumorigenicity and generates protective antitumor immunity Gene Therapy 1996 3: 531–541
Melero I et al. Amplification of tumor immunity by gene transfer of the co-stimulatory 4–1BB ligand: synergy with the CD28 co-stimulatory pathway Eur J Immunol 1998 28: 1116–1121
Lehnert K, Print CG, Yang Y, Krissansen GW . Mucosal addressin cell adhesion molecule-1 (MAdCAM-1) costimulates T cell proliferation exclusively through integrin α4β7 (LPAM-1), whereas VCAM-1 and CS-1 peptide use α4β1 (VLA-4): evidence for ‘remote’ costimulation and induction of hyperresponsiveness to B7 molecules Eur J Immunol 1998 28: 3605–3615
Berg RW, Yang Y, Lehnert K, Krissansen GW . Mouse M290 is the functional homologue of the human mucosal lymphocyte integrin HML-1: antagonism between the integrin ligandsE-cadherin and RGD tripeptide Immunol Cell Biol (in press)
Yang J-P, Huang I . Direct gene transfer to mouse melanoma by intratumor injection of free DNA Gene Therapy 1996 3: 542–548
Katsanis E et al. Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing Cancer Immunol Immunother 1994 38: 135–141
Naftzger C et al. Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity Proc Natl Acad Sci USA 1996 93: 14809–14814
Fakhari H et al. Eradication of established intracranial rat gliomas by transforming growth factor β antisense gene therapy Proc Natl Acad Sci USA 1996 93: 2909–2914
Strand S et al. Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells – mechanism of immune evasion? Nature Med 1996 2: 1361–1366
Zeytun A, Hassuneh M, Nagarkatti M, Nagarkatti PS . Fas-Fas ligand-based interactions between tumor cells and tumor-specific cytotoxic T lymphocytes: a lethal two-way street Blood 1997 90: 1952–1959
Lefor AT, Fabian DF . Enhanced cytolytic activity of tumor infiltrating lymphocytes (TILs) derived from an ICAM-1 transfected tumor in a murine model J Surg Res 1998 75: 49–53
Anichini A, Mortarini R, Supino R, Parmiani G . Human melanoma cells with high susceptibility to cell-mediated lysis can be identified on the basis of ICAM-1 phenotype, VLA profile and invasive ability Int J Cancer 1990 46: 508–515
Naganuma H et al. Increased susceptibility of IFN-gamma-treated neuroblastoma cells to lysis by lymphokine-activated killer cells: participation of ICAM-1 induction on target cells Int J Cancer 1991 47: 527–532
Nishio M et al. CD80 (B7.1) and CD54 (intracellular adhesion molecule-1) induce target susceptibility to promiscuous cytotoxic T cell lysis J Immunol 1996 157: 4347–4353
Komatsu F, Kajiwara M . A lymphokine-activated killer (LAK)-resistant cell line, and low expression of adhesion molecules LFA-3 and VCAM-1 on its cell surface Oncology Res 1998 10: 263–269
Damle NK et al. Costimulation of T lymphocytes with integrin ligands intercellular adhesion molecule-1 or vascular cell adhesion molecule-1 induces functional expression of CTLA-4, a second receptor for B7 J Immunol 1994 152: 2686–2697
Felzmann T, Ramsey WJ, Blaese RM . Anti-tumor immunity generated by tumor cells engineered to express B7–1 via retroviral or adenoviral gene transfer Cancer Lett 1999 135: 1–10
Cavallo F et al. Co-expression of B7.1 and ICAM-1 on tumors is required for rejection and the establishment of a memory response Eur J Immunol 1995 25: 1154–1162
Matulonis U et al. B7.1 is superior to B7.2 costimulation in the induction and maintenance of T cell-mediated antileukaemia immunity J Immunol 1996 156: 1126–1131
Nishio M, Podack ER . Rapid induction of tumor necrosis factor cytotoxicity in naïve splenic T cells by simultaneous CD80 (B7.1) and CD54 (ICAM-1) co-stimulation Eur J Immunol 1996 26: 2160–2164
Masinovsky B et al. IL-4 acts synergistically with IL-1 beta to promote lymphocyte adhesion to microvascular endothelium by induction of vascular cell adhesion molecule-1 J Immunol 1990 145: 2886–2895
Berlin C et al. α4β7 integrin mediates lymphocyte binding to the mucosal vascular addressin MAdCAM-1 Cell 1993 74: 185–195
Leung E et al. Cloning of the mucosal addressin MAdCAM-1 from human brain: identification of novel alternatively spliced transcripts Immunol Cell Biol 1996 74: 490–496
Freeman GJ et al. Cloning of B7.2: a CTLA-4 counter-receptor that costimulates human T cell proliferation Science 1993 262: 909–911
Briskin MJ, McEvoy LM, Butcher EC . MAdCAM-1 has homology to immunoglobulin and mucin-like adhesion receptors and to IgA1 Nature 1993 363: 461–464
Nagafuchi A et al. Transformation of cell adhesion properties by exogenously introduced E-cadherin cDNA Nature 1987 329: 341–343
Rimm DL, Morrow JS . Molecular cloning of human E-cadherin suggests a novel subdivision of the cadherin superfamily Biochem Biophys Res Commun 1994 200: 1754–1761
Azmi M, Field HJ . Cell-mediated antiviral response to equine herpesvirus type 1 demonstrated in a murine infection model by means of adoptive transfer of immune cells J Gen Virol 1993 74: 275–280
Acknowledgements
This work was supported in part by grants from the Royal Society of New Zealand, the Cancer Society of New Zealand, The Lottery Grants Board, The Leukaemia and Blood Foundation, the Health Research Council of New Zealand, and the Maurice and Phyllis Paykel Trust. GWK is a James Cook Research Fellow funded by the Royal Society of New Zealand.
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Kanwar, J., Berg, R., Lehnert, K. et al. Taking lessons from dendritic cells: multiple xenogeneic ligands for leukocyte integrins have the potential to stimulate anti-tumor immunity. Gene Ther 6, 1835–1844 (1999). https://doi.org/10.1038/sj.gt.3301016
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.gt.3301016
Keywords
This article is cited by
-
Treatment with HPMA copolymer-based doxorubicin conjugate containing human immunoglobulin induces long-lasting systemic anti-tumour immunity in mice
Cancer Immunology, Immunotherapy (2006)
-
Intramuscular delivery of antiangiogenic genes suppresses secondary metastases after removal of primary tumors
Cancer Gene Therapy (2005)
-
Regression of solid tumors by engineered overexpression of von Hippel–Lindau tumor suppressor protein and antisense hypoxia-inducible factor-1α
Gene Therapy (2003)
-
Requirements for ICAM-1 immunogene therapy of lymphoma
Cancer Gene Therapy (2003)
-
Mouse B7-H3 induces antitumor immunity
Gene Therapy (2003)